Agomab Therapeutics (AGMB) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, initially focusing on chronic fibrotic indications with high unmet medical need.

• Lead product candidates: ontunisertib (oral, GI-restricted ALK5 inhibitor for fibrostenosing Crohn's disease) and AGMB-447 (inhaled ALK5 inhibitor for idiopathic pulmonary fibrosis).

• Pipeline includes preclinical programs and AGMB-101, an HGF-mimetic monoclonal antibody for liver cirrhosis.

• Retains exclusive, worldwide development and commercialization rights to all product candidates.

Financial performance and metrics

• Reported net losses of €46.3 million in 2024 and €45.1 million for the nine months ended September 30, 2025.

• Accumulated loss of €164.3 million as of September 30, 2025.

• Cash and cash equivalents of €129.6 million as of September 30, 2025; pro forma as adjusted after IPO, cash and cash equivalents would be €283.2 million.

• R&D expenses increased to €39.3 million in 2024 and €35.0 million for the nine months ended September 30, 2025, reflecting clinical progress.

• No revenue generated to date; expects continued operating losses for the foreseeable future.

Use of proceeds and capital allocation

• Estimated net proceeds of $182 million from the IPO (or $210 million if underwriters exercise their option in full), based on an assumed price of $16.00 per ADS.

• Approximately $120 million allocated to advance ontunisertib through a planned global Phase 2b trial in FSCD.

• Approximately $80 million allocated to advance AGMB-447 through a planned Phase 2 trial in IPF.

• Remainder to fund preclinical candidates, general and administrative expenses, working capital, milestone payment for Origo Biopharma acquisition, and other corporate purposes.

• Funds expected to support operations until the first half of 2029.